Prognostic factors in malignant pleural mesothelioma: A retrospective study

Internal Medicine

Volumn 51, Issue 7, 2012, Pages 707-710

  Suzuki, Hidekazu ^a   Hirashima, Tomonori ^a   Kobayashi, Masashi ^a   Okamoto, Norio ^a   Matsuura, Yuka ^a   Tamiya, Motohiro ^a   Morishita, Naoko ^a   Okafuji, Kohei ^a   Shiroyama, Takayuki ^a   Morimura, Osamu ^a   Morita, Satomu ^a   Kawase, Ichiro ^a  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

Author keywords

Malignant pleural mesothelioma; Prognostic factor; Retrospective study

Indexed keywords

LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PLEURA MESOTHELIOMA; RETROSPECTIVE STUDY; SCORING SYSTEM; THORAX PAIN; THROMBOCYTE COUNT;

AGED; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; L-LACTATE DEHYDROGENASE; MALE; MESOTHELIOMA; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PLEURAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84859310581     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.6236     Document Type: Article

References (13)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 353: 1591-1603, 2005.
2. Kanazawa N, Ioka A, Tsukuma H, Ajiki W, Oshima A. Incidence and survival of mesothelioma in Osaka, Japan. Jpn J Clin Oncol 36: 254-257, 2006.
3. Muers MF, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 371: 1685-1694, 2008.
4. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16: 145-152, 1998.
5. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003.
6. Fennell DA, Parmar A, Shamash J, et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 23: 184-189, 2005.
7. Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O'Byrne KJ. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 55: 731-735, 2000.
8. Nowak AK, Francis RJ, Phillips MJ, et al. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. Clin Cancer Res 16: 2409-2417, 2010.
9. www.crab.orgIASLCMPMMPMStagingProject.pdf. (accessed in 2011).
10. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113: 723-731, 1998.
11. Nojiri S, Gemba K, Aoe K, et al. Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan. Jpn J Clin Oncol 41: 32-39, 2011.
12. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 10: 957-965, 2007.
13. Demirag F, Unsal E, Yilmaz A, Caglar A. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest 128: 3382-3387, 2005.